The Tumor Immunology and Immunotherapy Program in the University of Maryland Marlene and Stewart Greenebaum Cancer Center is dedicated to understanding the immune regulation of malignant disease, and translating this knowledge into the development of novel diagnostic, preventive, and treatment regimens. The program provides a forum to develop interdisciplinary strategies that promote innovative research, create new therapeutic options, and reduce the burden of cancer.
The principle scientific goals of the Tumor Immunology and Immunotherapy Program are to develop, characterize, and apply immunological approaches for the prevention, diagnosis, treatment, and monitoring of pre-malignant and malignant diseases and disease progression. Importantly, these four themes are dynamic and interactive, continually evolving to remain focused on clinical needs and translating programmatic data for treatment and prevention strategies. The ability to achieve these goals is enhanced by the interactive investigators with diverse expertise in clinical, translational, and basic science.
This program has four scientific aims: